CLINICAL CASE OF SUCCESSFUL TREATMENT OF METASTATIC COLORECTAL CANCER WITH ACHIEVEMENT OF COMPLETE PATHOMORPHOLOGICAL RESPONSE (FIRST LINE CHEMOTHERAPY)


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

There is an ongoing search for the most optimal chemotherapy regimens, the use of which is expected to increase the time to disease progression and overall survival, and improve the patients' quality of life. Due to significant advances in chemotherapy and surgical treatment of metastatic colorectal cancer, and the use of a multidisciplinary approach, algorithms of treatment of patients have been changed. Increase of patient’s life expectancy is observed with the use of all three most active drugs in this disease, i.e. oxaliplatin and irinotecan in combination with fluoropyrimidine±anti-EGFR-drugs. The article presents a case report of successful treatment of metastatic colorectal cancer with the achievement of a complete pathomorphological response due to simultaneous use of all these drugs in the 1st-line therapy.

全文:

受限制的访问

作者简介

A. Darenskaya

FSBI "RORC n.a. N.N. Blokhin" of RMH

Email: darenskaya@bk.ru
junior researcher at the scientific advisory department Moscow

N. Dobrova

FSBI "RORC n.a. N.N. Blokhin" of RMH

Moscow

L. Zhukova

FSBI "RORC n.a. N.N. Blokhin" of RMH

Moscow

B. Medvedeva

FSBI "RORC n.a. N.N. Blokhin" of RMH

Moscow

V. Mochalnikova

FSBI "RORC n.a. N.N. Blokhin" of RMH

Moscow

参考

  1. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer Incidence and Mortality Worldwide: IARC CancerBase. 2013, №. 11. Lyon, France: International Agency for Research on Cancer.
  2. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. 250 с.
  3. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями в России и странах СНГ в 2008 г. Вестник РОНЦ им. Н. Н. Блохина РАМН. 2010;21(2):52-86.
  4. Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 г. М., 2013.
  5. Grothey A., Sargent D., Goldberg R.M., Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 2004;22:120-914.
  6. Даренская А.Д., Доброва Н.В. Новый режим первой линии химиотерапии метастатического колоректального рака. Фарматека. 2014;8:5-761.
  7. Darenskaya A., Dobrova N., Lichinitser M. Oxaliplatin, irinotecan, and fluorouracil in the prolonged regimen for the Ist-line therapy of metastatic colorectal cancer: New therapy regimen. J. Clin. Oncol. 2015;33(15 suppl):e14617.
  8. Falcone A., Ricci S., Brunetti I., Pfanner E., Allegrini G., Barbara C., Crinc L., Benedetti G., Evangelista W., Fanchini L., Cortesi E., Picone V., Vitello S., Chiara S., Granetto C., Porcile G., Fioretto L., Orlandini C., Andreuccetti M., Masi G.; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 2007;25(13):1670-76.
  9. Masi G., Bursi S., Loupakis F., et al. Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases. ECCO. 2007; (4):аbstr. 3022.
  10. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P, Pitot H.C., Alberts S.R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004;22(1):23-30.
  11. de Gramont A, Figer A., Seymour M., Homerin M., Hmissi A, Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., de Braud F., Wilson C., Morvan F., Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000;18(16): 2938-47.
  12. Masi G., Vasile E., Loupakis F., Cupini S., Fornaro L., Baldi G., Salvatore L., Cremolini C., Stasi I., Brunetti i, Fabbri M.A., Puglisi M., Trenta P., Granetto C., Chiara S., Fioretto L., Allegrini G., Crino L., Andreuccetti M., Falcone A. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J. Natl. Cancer inst. 2011;103 (1):21-30.
  13. Peinert S., Grothe W., Stein A., Müller L.P., Ruessel J, Voigt W., Schmoll H.J., Arnold D. Safety and efficacy of weekly 5-fluorouracil/folinic acid/ oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. Ther. Adv. Med. Oncol. 2010;2(3):161-74.
  14. Samalin E, et al. WCGiC 2009;A PD-0011.
  15. Garufi C, et al. ASCO Gi 2008;abstr. 367.
  16. Garufi C., Torsello A., Tumolo S., et al. POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab)plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J. Clin. Oncol. 2009;27:suppl. abstr. e15020. 2009 ASCO Annual Meeting.
  17. Falcone A., Cremolini C., Masi G., et al. FOLFOXiRi/ bevacizumab (bev) vs. FOLFiRi/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase iii TRIBE trial by GONO group. J. Clin. Oncol. 2013;31(abstr. 3505).
  18. Bokemeyer C., Bondarenko i., Hartmann J.T., de Braud F., Schuch G., Zubel A., Celik i., Schlichting M., Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol. 2011;22(7):1535-46.
  19. ince W.L., Jubb A.M., Holden S.N., Holmgren E.B., Tobin P., Sridhar M., Hurwitz H.i., Kabbinavar F., Novotny W.F., Hillan K.J., Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl. Cancer inst. 2005;97(13):981-89.
  20. Souglakos J., Philips J., Wang R., Marwah S., Silver M., Tzardi M., Silver J., Ogino S., Hoosh-mand S., Kwak E., Freed E., Meyerhardt J.A., Saridaki Z., Georgoulias V., Finkelstein D., Fuchs C.S., Kulke M.H., Shivdasani R.A. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer. 2009;101(3):465-72.
  21. Tol J., Nagtegaal i.D., Punt C.J. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 2009;361(1):98-9.
  22. van Cutsem E., Köhne C.H., Lang i., Folprecht G., Nowacki M.P., Cascinu S., Shchepotin i., Maurel J., Cunningham D., Tejpar S., Schlichting M., Zubel A., Celik i., Rougier P., Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 2011;29(15):2011-19.
  23. Loupakis F., Schirripa M., Caparello C., et al. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXiRi plus bevacizumab. Brit J Cancer 2013;108:2549-56
  24. BursiS, Masi G, Loupakis F., et al. Capecitabin(C), in combination with irinotecan (i) and oxaliplatin(O) (XELOXiRi) as first-line treatment of metastatic colorectal cancer(MCRC): results of a pilot study by the Gruppo Oncologico Nord Ovest. ECCO 2007:5(4):abstr. 3063.
  25. Bajetta E., Celio L., Ferrario E., Di Bartolomeo M., Denaro A., Dotti K., Mancin M., Bajetta R., Colombo A., Pusceddu S. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase i/ii study in first-line treatment of metastatic colorectal cancer. Ann. Oncol. 2007;18 (11):1810-16.
  26. Schmoll H.J., van Cutsem E., Stein A., Valentini V., Glimelius B, Haustermans K., Nordlinger B., van de Velde C.J., Balmana J., Regula J., Nagtegaal i.D., Beets-Tan R.G., Arnold D., Ciardiello F., Hoff P., Kerr D., Köhne C.H., Labianca R., Price T., Scheithauer W., Sobrero A., Tabernero J., Aderka D., Barroso S., Bodoky G., Douillard J.Y., El Ghazaly H., Gallardo J., Garin A., Glynne-Jones R., Jordan K., Meshcheryakov A., Papamichail D., Pfeiffer P., Souglakos L., Turhal S., Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann. Oncol. 2012;23:2479-516
  27. Vasile E., Masi G., Fornaro L., Cupini S., Loupakis F., Bursi S., Petrini i., Di Donato S., Brunetti i.M., Ricci S., Antonuzzo A., Chiara S., Amoroso D., Andreuccetti M., Falcone A. A multicenter phase ii study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br. J. Cancer. 2009;100 (11):1720-24.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##